We are live on ! Find out more
MBRX icon

Moleculin Biotech
MBRX

12 hedge funds and large institutions have $5.16M invested in Moleculin Biotech in 2019 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

189% more capital inflows, than outflows

Capital inflows: $517K | Capital outflows: $179K

33% more funds holding

Funds holding: 9 → 12 (+3)

0.89% more ownership

Funds ownership: 9.4% → 10.29% (+0.89%)

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

Holders
12
Holders Change
+3
Holders Change %
+33.33%
% of All Funds
0.26%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
2
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$258K
2
Renaissance Technologies
Renaissance Technologies
New York
+$103K
3
ARTA
A.R.T. Advisors
New York
+$51.7K
4
Bank of New York Mellon
Bank of New York Mellon
New York
+$51.7K
5
Jane Street
Jane Street
New York
+$51.7K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$103K
2
BlackRock
BlackRock
New York
-$51.7K
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$20K
4
Archford Capital Strategies
Archford Capital Strategies
Illinois
-$4K

MBRX Hedge Fund Activity: Q3 2019 in Review

12 of the 4,576 institutional investors tracked by Wall St. Rank reported a position in Moleculin Biotech (MBRX) for Q3 2019, worth a combined $5.16M — down 2.8% from $5.31M a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new MBRX positions and 0 closed out — a net gain of 3 holders — while 2 added to existing stakes and 2 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $258K. The largest seller was Vanguard Group, cutting an estimated $103K.

  • 12 institutional investors held Moleculin Biotech (MBRX) as of Q3 2019, up from 9 in Q2 2019.
  • Funds reported $5.16M of Moleculin Biotech stock for Q3 2019, down 2.8% quarter-over-quarter.
  • 3 funds opened new Moleculin Biotech positions in Q3 2019 and 0 closed out, a net change of +3 holders.
  • The largest Moleculin Biotech buyer in Q3 2019 was Millennium Management, an estimated $258K added.
  • The largest Moleculin Biotech seller in Q3 2019 was Vanguard Group, an estimated $103K sold.

Based on aggregated 13F filings for Q3 2019.